Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Yamamoto, Sena; Kondoh, Chiharu; Nakagoshi, Hideko; Kakumen, Mayuko; Yasuhara, Kana; Nakai, Mayumi; Kodani, Naoko; Sunda, Kazumi; Higashide, Chizuru; Katayama, Megumi; Arao, Harue

doi:https://doi.org/10.1007/s10147-024-02479-2

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Yamamoto, Sena; Kondoh, Chiharu; Nakagoshi, Hideko et al.

International Journal of Clinical Oncology, 2024, 6, 166

アクセス数:646件（2025-10-24 01:16 集計）

固定URL: https://hdl.handle.net/11094/94699

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
IntJClinOncol_6_166	pdf	なし	728 KB	271	2024.03.18

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
著者	NRID 1000060796522 1000060796522 researchmap permalink 60796522 60796522 Scopus Author ID 57188590410 57188590410 著者名 Yamamoto, Sena
	著者名 Kondoh, Chiharu
	著者名 Nakagoshi, Hideko
	著者名 Kakumen, Mayuko
	著者名 Yasuhara, Kana
	著者名 Nakai, Mayumi
	著者名 Kodani, Naoko
	著者名 Sunda, Kazumi
	著者名 Higashide, Chizuru
	著者名 Katayama, Megumi
	NRID 1000050326302 1000050326302 researchmap permalink read0201 read0201 Scopus Author ID 16311856300 16311856300 著者名 Arao, Harue
キーワード等	Cancer
	Financial toxicity
	Molecular targeted therapy
	Immunotherapy
内容	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02479-2.
抄録	Background: Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity of patients treated with molecular-targeted and immune therapies and explore the relationship between financial toxicity and patient experiences associated with the financial burden of cancer treatment. Methods: This anonymous, self-administered questionnaire survey conducted across nine hospitals in Japan included patients aged 20–60 years who were receiving molecular-targeted agents or immune checkpoint inhibitors for any type of cancer for ≥ 2 months. Financial toxicity was evaluated using the COmprehensive Score for Financial Toxicity (COST). Patient experience was examined using 11 items based on previous studies. Independent factors related to financial toxicity were explored using multiple regression analyses. Results: The mean COST score was 17.0 ± 8.4, and 68 (49.3%) participants reported COST scores at or below the cutoff point. The factors contributing to financial toxicity were “hesitation regarding continuing treatment based on finances” (sβ = − 0.410, p < 0.001), “cutting through my deposits and savings” (sβ = − 0.253, p = 0.003), and “reducing spending on basics like food or clothing” (sβ = − 0.205, p = 0.046) along with comorbidities (sβ = − 0.156, p = 0.032). Conclusion: Patients receiving molecular-targeted and immune therapies are at risk of experiencing profound financial toxic- ity and a reduced quality of life. The independently related factors that we identified have the potential to serve as indicators of profound financial toxicity and the need for specialized intervention.
出版者	Springer Science and Business Media LLC
収録物名	International Journal of Clinical Oncology
巻(号)	6
ページ	166
刊行年月	2024-02-24
言語	英語
ハンドルURL	https://hdl.handle.net/11094/94699
PISSN	13419625
eISSN	14377772
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10147-024-02479-2
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	International Journal of Clinical Oncology. 2024, 6, p. 166
DC.title	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
DC.creator	Yamamoto, Sena
	Kondoh, Chiharu
	Nakagoshi, Hideko
	Kakumen, Mayuko
	Yasuhara, Kana
	Nakai, Mayumi
	Kodani, Naoko
	Sunda, Kazumi
	Higashide, Chizuru
	Katayama, Megumi
	Arao, Harue
DC.publisher	Springer Science and Business Media LLC
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-02-24
DC.identifier	https://doi.org/10.1007/s10147-024-02479-2
DC.subject	Cancer
	Financial toxicity
	Molecular targeted therapy
	Immunotherapy
DC.description	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02479-2.
DCTERMS.abstract	Background: Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity of patients treated with molecular-targeted and immune therapies and explore the relationship between financial toxicity and patient experiences associated with the financial burden of cancer treatment. Methods: This anonymous, self-administered questionnaire survey conducted across nine hospitals in Japan included patients aged 20–60 years who were receiving molecular-targeted agents or immune checkpoint inhibitors for any type of cancer for ≥ 2 months. Financial toxicity was evaluated using the COmprehensive Score for Financial Toxicity (COST). Patient experience was examined using 11 items based on previous studies. Independent factors related to financial toxicity were explored using multiple regression analyses. Results: The mean COST score was 17.0 ± 8.4, and 68 (49.3%) participants reported COST scores at or below the cutoff point. The factors contributing to financial toxicity were “hesitation regarding continuing treatment based on finances” (sβ = − 0.410, p < 0.001), “cutting through my deposits and savings” (sβ = − 0.253, p = 0.003), and “reducing spending on basics like food or clothing” (sβ = − 0.205, p = 0.046) along with comorbidities (sβ = − 0.156, p = 0.032). Conclusion: Patients receiving molecular-targeted and immune therapies are at risk of experiencing profound financial toxic- ity and a reduced quality of life. The independently related factors that we identified have the potential to serve as indicators of profound financial toxicity and the need for specialized intervention.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94699
citation_title	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
citation_author	Yamamoto, Sena
	Kondoh, Chiharu
	Nakagoshi, Hideko
	Kakumen, Mayuko
	Yasuhara, Kana
	Nakai, Mayumi
	Kodani, Naoko
	Sunda, Kazumi
	Higashide, Chizuru
	Katayama, Megumi
	Arao, Harue
citation_publisher	Springer Science and Business Media LLC
citation_language	英語
citation_date	2024-02-24
citation_journal_title	International Journal of Clinical Oncology
citation_volume	6
citation_firstpage	166
citation_doi	https://doi.org/10.1007/s10147-024-02479-2
citation_public_url	https://hdl.handle.net/11094/94699

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

閲覧可能ファイル

論文情報

論文詳細を表示